Atrial Fibrillation

Management Strategies
Marc D. Schrode, D.O., F.A.C.C., F.A.C.O.I.
Atrial Fibrillation

• Estimated that 2.6 to 6.1 million people in the U.S. with Afib as of 2010
• By 2050 it is expected that Afib will affect nearly 5.6 to 12 million Americans
• The percentage of strokes attributable to afib increases steeply from 1.5% at 50-59 years of age to 23.5% at 80-89 years of age
Atrial Fibrillation Treatment Approach

- Rate Control vs Rhythm Control Strategies
- Integrated consideration:
  - Degree of symptoms
  - Likelihood of successful cardioversion
  - Presence of comorbidities
  - Candidacy for Afib ablation
Rhythm Control

- Improves cardiac hemodynamics
- Improves exercise tolerance
- Possibly reverses atrial dilatation
- Possibly improves quality of life
AFFIRM
Atrial Fibrillation Follow-up Investigation of Rhythm Management

- 4060 subjects age 65 or greater with afib randomized to strategy of rhythm control (cardioversion plus drugs) versus strategy of rate control (no attempt to restore sinus rhythm)
- No difference in rate of stroke or death between rate control and rhythm control strategies
Management of New-onset Afib
Rate Control vs Rhythm Control

• General recommendations: Rate Control
  • Asymptomatic
  • Older patients
  • Minimally symptomatic with HTN or other co-morbidities

• General recommendations: Rhythm Control
  • Younger
  • Highly symptomatic
  • Few co-morbidities
Rate Control Strategy

- A number of Intrinsic and extrinsic factors affect ventricular rate
- Intrinsic AV nodal condition properties
- Underlying sympathetic and parasympathetic tone
Rate Control Strategy

- First line agents:
  - Beta Blockers
  - Calcium Channel Blockers
  - Effective both at rest and with exertion
  - IV forms
  - Caution with beta blockers and patients with reactive airway disease
Rate Control Strategy

- Digoxin
  - Rarely used as monotherapy
  - Poorly effective in active settings
  - Heart failure and reduced LV function may make a good choice of therapy
Rate Control Strategy

- Amiodarone
  - IIA recommendation for those intolerant or unresponsive to other agents
  - Patients who do not tolerate Beta Blockers or Calcium Channel Blockers, such as patients with CHF may be good candidates
Rhythm Control Strategy

- Many physicians believe that an attempt at rhythm control should be made in most patients.
- In general: younger patients with more severe symptoms and fewer co-morbidities a rhythm control strategy is appropriate. In older patients with structural heart disease, less likely to maintain SR and more likely to have side effects from antiarrhythmic drugs, a rate control strategy would be reasonable.
Rhythm Control Strategy

- Several antiarhythmic drugs have established efficacy in pharmacologic conversion of Afib to sinus rhythm
  - Flecainide
  - Propafenone
  - Dofetilide
  - Amiodarone
Amiodarone

- Patients with CAD, systolic or diastolic HF, amiodarone becomes drug of choice because of its decreased proarrhythmic effects compared to other antiarrhythmic agents.
- Amiodarone more effective in maintaining sinus rhythm in Canadian Trial of Atrial Fibrillation (CTAF) and Sotalol Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T).
Dronedarone

- 2011 update to ACCF/AHA/HRS Afib guidelines add that it is reasonable to use dronaderone to reduce the probability that hospitalization will be required for patients with paroxysmal Afib or after cardioversion of persistent Afib
- Contradindicated in class IV HF or a recent episode of decompensated HF
- Not approved for patients with permanent AF
  - PACCAS study, 2 fold rise in death and 2 fold increase in strokes and heart failure hospitalizations
Sotalol

- Class III drug
- Monitor QTc
- Increased risk of QT prolongation and torsade de pointes
- Proarrhythmic effects increased in patients with CHF (unlike amiodarone and dofetilide)
- Hypokalemia should be corrected and avoided (prolongs QT)
Afib Risk Management

- Overall, approximately 15-25% of all strokes in U.S. can be attributed to Afib
- Benefits in terms of stroke prevention weighed against risk of serious bleeding
## Afib and Stroke Risk

### Risk Factors
- Prior Stroke/TIA
- History of HTN
- HF or reduced LV function
- Advanced age
- Diabetes
- CAD

### Relative Risk
- 2.5
- 1.6
- 1.4
- 1.4
- 1.7
- 1.5
CHADS2 Score

- Cardiac Failure
- Hypertension
- Age > 75
- Diabetes
- Previous Stroke or TIA (2 points)
<table>
<thead>
<tr>
<th>CHADS2 Score</th>
<th>Adjusted Stroke Rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>1.9%</td>
</tr>
<tr>
<td>1</td>
<td>2.8%</td>
</tr>
<tr>
<td>2</td>
<td>4.0%</td>
</tr>
<tr>
<td>3</td>
<td>5.9%</td>
</tr>
<tr>
<td>4</td>
<td>8.5%</td>
</tr>
<tr>
<td>5</td>
<td>12.5%</td>
</tr>
<tr>
<td>6</td>
<td>18.2%</td>
</tr>
</tbody>
</table>
CHADS2-VASc Score

- Adds Vascular Disease and Sex into formula
- Can be estimated with online calculator
- Better at predicting high risk and low risk subjects
CHADS2 Score and Therapy Recommendations

**Risk Score**
- No risk factors
- 1 moderate risk factor
- 2 or greater

**Recommended Therapy**
- ASA 81-325 mg
- ASA 81-325 mg or Warfarin
- Warfarin (INR 2-3)
Risk Factors

- Hi risk factors: prior CVA, TIA or systemic embolization
- Risk factors of unknown significance:
  - Female sex
  - Age 65-74
  - CAD
  - Thyrotoxicosis
Warfarin for Stroke Prevention

- At least 4 large trials have clearly demonstrated that anticoagulation with warfarin decreases risk of stroke by 50-80%
- Warfarin superior to Clopidogrel or ASA/Clopidogrel in prevention of stroke in higher risk patients
- Once again, stroke risk vs bleeding risk needs to be considered
Electrical Cardioversion

- Urgent Cardioversion:
  - Hemodynamically unstable
  - Severe dyspnea
  - Chest pain
  - Pre-excited Afib
DC Cardioversion

- Delivery of electrical current that is synchronized to QRS complexes
- Monophasic or biphasic forms
- Sedation
- Success rate > 75%
- Most important complication is embolization, if <48 hrs generally safe to proceed, if >48 hrs TEE guided or 3-4 weeks of anticoagulation recommended
- Stunning of atrium and stasis can occur despite SR, therefore 4 weeks of anticoagulation is recommended
DC Cardioversion

- Other potential complications:
  - Pulmonary edema
  - Hypotension
  - Myocardial dysfunction
  - Skin burns
DC Cardioversion Paddle/Patches

- Anterolateral (Ventricular Apex and Right infraclavicular
- Anterior-Posterior (Sternum and left Scapular)
- One study A-P position increased efficacy
Pharmacologic Cardioversion

- “Pill-in-the-Pocket” approach
  - Flecainide 300 mg (>60 kg)  200 mg (<60 kg)
  - Propafenone 600 mg (>60 kg)  450 mg (<60 kg)
- Sotalol
  - Inpatient monitoring
  - Patients with no heart disease, with QTc < 450 ms and normal electrolytes could be started as outpatient
- Ibutilide (Corvert)
  - 1 mg (>60 kg) over 10 min and repeat if necessary
- Amiodarone, flecainide, ibutilide, propafenone or sotalol alone or in combination with DC cardioversion
Atrial Fibrillation Catheter Ablation

- 2011 ACCF/AHA/HRS AF Guidelines
  - It is recommended as an alternative to pharmacologic therapy to prevent recurrent paroxysmal afib in significantly symptomatic patients with little or no structural heart disease or pulmonary disease (Class 1, evidence level A)
  - It is reasonable as a treatment for symptomatic persistent Afib
  - Catheter ablation may be reasonable as a treatment for symptomatic paroxysmal Afib in patients with structural heart disease
Afib Catheter Ablation

- Afib catheter ablation may be superior to AV nodal ablation and biventricular pacing in heart failure patients but is technically difficult and more demanding
Catheter ablation vs minimally invasive surgical ablation

- Boersma et al found that patients with AF who had a dilated left atrium and hypertension or who failed prior AF ablation, surgical ablation was superior in achieving freedom for left atrial arrhythmias after 12 months of followup; however, procedural adverse event rate was significantly higher with surgical ablation, primarily postoperative pneumothorax, major bleeding and an increased need for a permanent pacemaker.
New Medical and Device Based Rhythm Control Strategies

- Renin-angiotensin system antagonists
- Statins
- Single and dual site atrial pacemakers to prevent AF
- Atrial defibrillators
- New surgical and catheter based therapies to compartmentalize the atria and localize focal triggers
Stroke Prevention

- Warfarin
- Dabigatran (Pradaxa)
- Rivaroxaban (Xarelto)
- Apixaban (Eliquis)
- ASA
- Clopidogrel
Risk of Bleeding

- ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation Study)
- 5-Point risk factor stratification scheme
  - Anemia
  - Severe Renal Disease
  - Age
  - Prior Bleeding
  - Hypertension
HEMORR2HAGES

- Hx of bleeding 2 points
- Hepatic or renal dz 1 pt
- Alcohol abuse 1 point
- Malignancy 1 point
- Age > 75 1 point
- Reduced platelet count or ASA therapy 1 pt
- HTN 1 point
- Anemia 1 point
- Genetic predisp. 1 point
- Excessive fall risk 1 point
- Stroke 1 point

- Bleeding event per 100 patient-years
  - 0 points- 1.9%
  - 1 point- 2.5%
  - 2 points- 5.3%
  - 3 points- 8.4%
  - 4 points- 10.4%
  - 5 points- 12.3%
2011 ACCF/AHA/HRS Guidelines

- If warfarin not to be used, adding clopidogrel to ASA may be considered
Dabigatran
Pradaxa

- Class 1b: Treatment considered useful/effective based on single randomized trial
- May be used as alternative to warfarin for prevention of stroke and systemic embolus in patients with paroxysmal or permanent atrial fibrillation
- Direct Thrombin Inhibitor
RE-LY

- 18,000 patients with Afib
- Randomized to 1 of 3 arms
  - 1. Adjusted dose warfarin
  - 2. Dabigatron 110 mg bid
  - 3. Dabigatron 150 mg bid
- Dabigatron 110 mg was noninferior to warfarin to primary efficacy endpoint of stroke or systemic embolization
- Dabigatron 150 mg was significantly more effective than warfarin or Dabigatron 110 mg
RE-LY

Bleeding

- Major bleeding occurred significantly less often with Dabigatron 110 mg than warfarin
- Dabigatron 150 mg had similar bleeding to warfarin
Patients not a candidate for Dabigatron

- Prosthetic Heart Valves
- Hemodynamically significant valvular heart disease
- Renal Failure: CrCl < 15 ml/min
- Advanced Liver Disease
Dabigatran Administration

- Capsule (do not crush, chew or break)
- < 18 years of age: safety and efficacy not established
- Missed dose: take as soon as possible on same day; skip dose if cannot be taken at least 6 hrs before next scheduled dose. Do not double dose to make up for a missed dose
Dabigatran
Renal impairment

- > 30 ml/min  150 mg bid
- Moderate (30-50 ml/min) plus P-Glycoprotein inhibitor (ie. Dronaderone, ketoconazole) decrease to 75 mg bid
- Severe (15-30 ml/min) decrease to 75 mg bid
- < 15 ml/min or dialysis: No data available
Dose Conversion
Warfarin/Heparin/Lovenox to Dabigatran

- Discontinue warfarin and initiate Dabigatran when INR < 2.0
- IV Heparin: initiate at time of discontinuing IV heparin
- SQ Lovenox: give 0-2 hrs before next dose
Dose Conversion
Dabigatron to Warfarin

- **CrCl > 50 ml/min**: start warfarin 3 days before d/c of Dabigatron
- **CrCl 30-50 ml/min**: start warfarin 2 days before d/c of Dabigatron
- **CrCl 15-30 ml/min**: start warfarin 1 day before d/c of Dabigatron
- **CrCl < 15 ml/min**: no recommendations
Dose Conversion
Parenteral Anticoagulation from Dabigatran

- CrCl > 30 ml/min: wait 12 hrs after last dose
- CrCl < 30 ml/min: wait 24 hrs after last dose
Rivaroxaban
Xarelto

- Factor Xa inhibitor
- Oral bioavailability
- Rapid onset of action
ROCKET AF

- Multinational trial
- Double blind
- Over 14,000 patients
- Rivaroxaban vs warfarin
- Noninferior to warfarin in prevention of stroke and thromboembolism
- Intracranial hemorrhage and fatal bleeding less in Rivaroxaban arm
- Note: only 57.8% optimal INR in warfarin arm
EINSTEIN Trial

- Compare safety and efficacy of Rivaroxaban with standard therapy
- 3,449 patients with DVT
- Rivaroxaban or Enoxaparin/Warfarin
- Duration: 3, 6 or 12 months – physician discretion
- Primary efficacy outcome: symptomatic recurrent venous thromboembolism
- Primary safety outcome: composite of major bleeding and clinically relevant nonmajor bleeding
Rivaroxaban had noninferior efficacy with respect to primary outcome 2.1% vs 3.0%

Primary safety outcome 8.1% in each group

In continued-treatment study, Rivaroxaban had superior efficacy 8 (1.3%) events vs 42 (7.1%) events. Four patients in Rivaroxaban group had nonfatal major bleed versus none in other group.
Conclusion: Rivaroxaban offers a simple, single drug approach to the short-term and continuous treatment of venous thrombosis that may improve the benefit-to-risk profile of anticoagulation
EINSTEIN-PE

• Compare safety and efficacy of Rivaroxaban with standard therapy
• 4,832 patients with confirmed PE
• Rivaroxaban or Enoxaparin/Warfarin
• Treatment duration: 3, 6 or 12 months – physician discretion
• Primary efficacy outcome: symptomatic recurrent venous thromboembolism
• Primary safety outcome: composite of major bleeding and clinically relevant nonmajor bleeding
Rivaroxaban was noninferior to standard therapy with 50 events in the Rivaroxaban group versus 44 events in the standard-therapy group.

Principal safety outcome occurred in 10.3% of the Rivaroxaban group and 11.4% of those in the standard-therapy group.

Major bleeding observed in 1.1% of the Rivaroxaban group and 2.2% of the standard-therapy group.
EINSTEIN-PE

- Conclusion: A fixed-dose regimen of Rivaroxaban alone was non-inferior to standard therapy for the initial and long-term treatment of pulmonary embolism and a potentially improved benefit-risk profile
Rivaroxaban (Xarelto) Dosing

- **DVT prophylaxis**
  - Knee replacement: 10 mg daily for 12 days
  - Hip replacement: 10 mg daily for 35 days
- **DVT and PE Treatment**
  - 15 mg q12 hrs for 21 days then 20 mg daily for 6 months
- **Nonvalvular Afib**
  - 20 mg daily for with evening meal
Rivaroxaban (Xarelto)
Discontinuation for surgery/procedure

- Stop Rivaroxaban at least 24 hrs before procedure
- Restart after surgery/procedure as soon as adequate hemostasis is established
- Consider parenteral drug if unable to take PO
Switching

- Warfarin to Rivaroxaban
- D/C warfarin and start rivaroxaban as soon as INR below 3.0

Rivaroxaban to warfarin
No clinical data available
INR measurements made during coadministration may not be useful

One approach: start coumadin and parenteral agent at the time next dose of Rivaroxaban would have been taken
Rivaroxaban (Xarelto) Administration

- Forms: 10 mg, 15 mg and 20 mg tablets
- 15 and 20 mg tablets may be crushed and mixed with applesauce or food. Dose should be immediately followed with food
Rivaroxaban (Xarelto)
Dosing Modifications

- Renal impairment
  - CrCl > 50 ml/min 20 mg daily with evening meal
  - CrCl 15-50 ml/min 15 mg daily with evening meal
  - Cr Cl < 15 ml/min avoid use
- Avoid use in patients with moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment or with any hepatic disease with associated coagulopathy
Apixaban
Eliquis

• Factor Xa inhibitor
• Approved Dec. 2012 for stroke prevention treatment of patients with nonvalvular AFib
ARISTOTLE
Apixaban for Reduction in Strokes and Other Thromboemoblic Events

- Apixaban versus Warfarin
- Nonvalvular Afib with at least 1 risk factor for stroke
- Apixaban superior to warfarin in preventing stroke with less bleeding and lower mortality
AVERROES
Apixaban versus Actysalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment

- Apixaban versus ASA in patient when warfarin therapy was considered unsuitable
- Stopped early because significant reduction in stroke and systemic embolism compared to ASA
- Modest increase in bleeding in Apixaban arm
Apixaban
Eliquis

• Nonvalvular Afib patients
• Indicated to reduce risk of stroke and systemic embolism associated with nonvalvular afib
• 5 mg bid
Apixaban (Eliquis)
Dosage Modifications

- Coadministration with strong dual inhibitors of CYP3A4 and P-gp: decrease dose to 2.5 mg PO BID
- Decrease dose to 2.5 mg PO BID in patients with at least 2 of following characteristics: Age > 80, weight < 60 kg or serum creat < 1.5 mg/dl
- CrCl < 15 mg/min: No data available
- Hepatic impairment
  - Mild: No dosage adjustment required
  - Mod: No recommendations available
  - Severe: No recommendations available
Cost Considerations

- Warfarin 30 days cost
- Pradaxa 30 day cost
- Xarelto 30 day cost
- Eliquis 30 day cost

- $17
- $317
- $304
- $298
Cost Considerations

- Commercial Insurance patients with multiple programs to reduce costs
- Cost of Prothrombin Time/INR $28 for lab and $19 draw fee to patient or insurance carrier